Connetics licenses technology for treatment of hyperhidrosis

By Ted A. Knutson

Washington, March 7 - Connetics Corp. said Tuesday it has obtained an exclusive, worldwide license to certain patented technology that has potential utility in the treatment of hyperhidrosis.

Connetics has begun a formulation development program using this technology with the goal of developing a safe, effective, well-tolerated and cosmetically elegant topical formulation. Connetics intends to begin clinical development immediately after completion of the formulation development activities.

Financial terms include upfront, milestone and royalty payments.

The company did not reveal the individual or company it obtained the license from and the price of the license.

Hyperhidrosis is a disorder characterized by excessive sweating that is estimated to affect more than 7 million Americans. This excessive sweating can occur in the hands (palmar hyperhidrosis), in the armpits (axillary hyperhidrosis) or in the feet (plantar hyperhidrosis) and may be triggered by stress, emotion or exercise, but can also occur spontaneously. Patients with palmar hyperhidrosis often find it awkward to shake hands with others and difficult to grasp objects.

Those who suffer from axillary hyperhidrosis often have stained clothes as a result of excessive sweat from their underarms. Patients with plantar hyperhidrosis are left with moist socks and shoes, as well as increased foot odor.

Connetics is a Palo Alto, Calif.-based specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.